Archived research. Equity forecasting is part of the Runchey Research archive (methodology era 1) and is no longer actively updated. Everything remains published at its original URL. Browse the archive
Will Quest co-promotion contribute materially to Shield volumes by H2 2026?
Current Prediction
Why This Question Matters
Quest co-promotion is a key infrastructure catalyst for Shield distribution at scale.
Prediction Distribution
Individual Predictions(9 runs)
Channel partnerships take time to ramp. Quest has the infrastructure but integrating a novel screening test into existing workflows requires training and process changes.
10% of volumes is a meaningful threshold. Quest would need to generate 10K+ tests per quarter in H2 to be material. This requires significant ramp from early partnership stages.
Quest has nationwide reach and established physician relationships. If the partnership is well-executed, 10% contribution is feasible but represents optimistic execution.
Lab partnerships for novel tests typically take 12-18 months to reach meaningful volumes. H2 2026 may be early for material contribution.
The resolution criteria require management disclosure of materiality. Even if Quest contributes, it may not be separately disclosed as material.
Quest has strong sales infrastructure. If the commercial agreement is well-structured with aligned incentives, ramp could be faster than typical.
Partnership ramp takes time. 10% is meaningful threshold. ~40%.
Early for material contribution. ~38%.
Quest infrastructure helps but novel test integration is slow. ~42%.
Resolution Criteria
Resolves YES if Quest channels contribute >10% of Shield test volumes in H2 2026. Resolves NO if below 10% or not disclosed.
Resolution Source
Guardant Health earnings calls or investor presentations
Source Trigger
Quest co-promotion is a key infrastructure catalyst for Shield distribution at scale
Full multi-lens equity analysis